GH13-006: RESEARCH AND TECHNICAL ASSISTANCE FO REPUBLIC HEALTH INT

GH13-006：共和国卫生情报研究和技术援助

• 批准号: 9016652
• 负责人: WEDNER PIERRE
• 金额: $ 30万
• 依托单位: MOH/BUILD/STRENGTHEN/HAITI'S PLAN/PREVEN
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-30 至 2018-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9016652
• 关键词: GH13; 006; RESEARCH; TECHNICAL; ASSISTANCE

DESCRIPTION (provided by the applicant): The project aims to build the capacity of the Ministry of Health in Haiti to conduct, interpret, disseminate, and respond to assessments, surveys and other evaluations through the implementation of four specific research projects: The first study will focus on the seroprevalence of various specific pediatric infections in Haiti and will be carried out by enrolling 1200 children ages 5-10 and collecting Serum and DBS (dry blood spot) samples to be tested at the National Public Health Laboratory (LNSP) with a focus on vaccine preventable diseases including hepatitis B (ELISA) and IFA for rubella and measles. Analysis will focus on descriptive measures of disease prevalence and patient characteristics associated with various infections. The second study will focus on evaluation of the impact of pneumococcal conjugate vaccine by enrolling approximately 500 children evenly distributed from 0 to 5 years of age and collecting nasopharyngeal specimens to be tested via isolation and conventional serotyping methods at the National Public Health Reference lab in Port-au-Prince. The third study will assess the determinants of HIV mortality through two rounds, retrospective and prospective. The target population will be HIV positive adults of both sexes aged 18 years seen at 15 health institutions from 2005-2009 and the study will compare the survival of ARV-treated versus PLHIV that did not receive treatment. The fourth study will focus on early treatment of PLHIV compared to the standard of care (after CD4 determination. Patients in the test and treat arm will receive treatment within a week of diagnosis concurrent with the "pretreatment preparation" counseling. The standard of care arm will receive treatment as per current practice (when CD4 <350 and after, pretreatment counseling). All participants will be tested periodically for VL and drug resistance when suppression is not reached (VL > 1000). The primary outcome of the study will be viral load (VL) suppression at 12 months after initiation of therapy. Outcomes will be measured for a period of 5 years.

描述（申请人提供）： 该项目旨在通过实施四个特定的研究项目来建立海地卫生部在海地进行，解释，传播和回应评估，调查和其他评估的能力： 第一项研究将重点介绍海地各种特定儿科感染的血清阳性，并将通过注册1200名5-10岁的儿童，并收集在国家公共卫生实验室（LNSP）测试的血清和DBS（干血点）样本，重点是可预防疫苗的疾病，包括可预防疫苗（包括海上性疾病）和IFA（Elisa）和IFA（IFA）和IFA。分析将侧重于与各种感染相关的疾病患病率和患者特征的描述性测量。 第二项研究将着重于评估肺炎球菌结合疫苗的影响 注册大约500名儿童从0到5岁均匀分配并收集 鼻咽标本将在port-au-rince的国家公共卫生参考实验室通过隔离和常规血清分型方法进行测试。 第三项研究将通过两轮回顾性评估HIV死亡率的决定因素 和潜在的。目标人群将是2005年至2009年在15个卫生机构中看到的18岁男性的艾滋病毒阳性成年人，该研究将比较未接受治疗的ARV治疗与PLHIV的生存。 The fourth study will focus on early treatment of PLHIV compared to the standard of care (after CD4 determination. Patients in the test and treat arm will receive treatment within a week of diagnosis concurrent with the "pretreatment preparation" counseling. The standard of care arm will receive treatment as per current practice (when CD4 <350 and after, pretreatment counseling). All participants will be tested periodically for VL and drug resistance when suppression is not reached (VL > 1000）。 结果将衡量5年。